High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/μl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients) | Publicación